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Abstract
Background: The United Kingdom Myeloma Research Alliance (UK-MRA) Myeloma Risk Profile is a prognostic
model for overall survival. It was trained and tested on clinical trial data, aiming to improve the stratification of
transplant ineligible (TNE) patients with newly diagnosed multiple myeloma. Missing data is a common problem
which affects the development and validation of prognostic models, where decisions on how to address
missingness have implications on the choice of methodology.
Methods:
Model building
The training and test datasets were the TNE pathways from two large randomised multicentre, phase III clinical
trials. Potential prognostic factors were identified by expert opinion. Missing data in the training dataset was
imputed using multiple imputation by chained equations. Univariate analysis fitted Cox proportional hazards
models in each imputed dataset with the estimates combined by Rubin’s rules. Multivariable analysis applied
penalised Cox regression models, with a fixed penalty term across the imputed datasets. The estimates from each
imputed dataset and bootstrap standard errors were combined by Rubin’s rules to define the prognostic model.
Model assessment
Calibration was assessed by visualising the observed and predicted probabilities across the imputed datasets.
Discrimination was assessed by combining the prognostic separation D-statistic from each imputed dataset by
Rubin’s rules.
Model validation
The D-statistic was applied in a bootstrap internal validation process in the training dataset and an external
validation process in the test dataset, where acceptable performance was pre-specified.
Development of risk groups
Risk groups were defined using the tertiles of the combined prognostic index, obtained by combining the
prognostic index from each imputed dataset by Rubin’s rules.
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Results: The training dataset included 1852 patients, 1268 (68.47%) with complete case data. Ten imputed datasets
were generated. Five hundred twenty patients were included in the test dataset. The D-statistic for the prognostic
model was 0.840 (95% CI 0.716–0.964) in the training dataset and 0.654 (95% CI 0.497–0.811) in the test dataset and
the corrected D-Statistic was 0.801.
Conclusion: The decision to impute missing covariate data in the training dataset influenced the methods
implemented to train and test the model. To extend current literature and aid future researchers, we have
presented a detailed example of one approach. Whilst our example is not without limitations, a benefit is that all of
the patient information available in the training dataset was utilised to develop the model.
Trial registration: Both trials were registered; Myeloma IX-ISRCTN68454111, registered 21 September 2000.
Myeloma XI-ISRCTN49407852, registered 24 June 2009.
Keywords: Prognostic Model, Multiple imputation, Missing data, Overall survival
Background
Multiple myeloma is a cancer of blood plasma cells of
which there are 5000 new cases in the UK each year [1].
At diagnosis, patients are stratified into transplant eli-
gible (TE) or transplant ineligible (TNE) groups by their
treating clinician, determining whether they will receive
high or low intensity treatment. Recent improvements in
outcomes for patients with multiple myeloma have bene-
fited TE patients over TNE patients [2]. There is a need
to determine whether TNE patients can be stratified fur-
ther in the context of their survival outcomes, so that
treatment can be personalised and survival potentially
improved.
A prognostic model can be used both to predict
individuals’ risk of a future event and stratify pa-
tients. In the literature there are five areas com-
monly discussed concerning the development and
validation of prognostic models: preliminary work,
model building, model assessment, validation (in-
ternal and external) and the development of risk
groups [3–6]. Preliminary work focuses on identify-
ing both the data to develop the prognostic model
(the training dataset) and the data in which to assess
the developed model (the test dataset). It is also the
stage when the variables (prognostic factors) to be
considered for inclusion in the prognostic model are
identified. Model building is concerned with develop-
ing the prognostic model, alongside deciding on how
to handle any missing data. Model assessment con-
siders how the developed prognostic model performs
by investigating both the calibration (how well the
predicted probabilities of the event of interest from
the prognostic model match the empirical probabil-
ities) and discrimination (whether those who experi-
ence the outcome of interest will be predicted to
have it). Model validation considers both how the
prognostic model performs in the training dataset
(internal validation) and in the test dataset (external
validation). Finally, the development of risk groups
suggests how the prognostic model can be used to
stratify patients into how likely they are to experi-
ence the outcome, which in this study was survival.
Missing data is not uncommon in the development
of prognostic models and is an issue as it reduces the
information available to build the model [7]. Rather
than discard the observations or variables with miss-
ing information, it is suggested to impute any missing
data, with sophisticated methods such as multiple im-
putation being advocated [4]. However, few published
models implement imputation, particularly when con-
sidering survival outcomes [7–9]. Furthermore, the
implications of multiple imputation on model devel-
opment and validation are rarely discussed in publica-
tions, with the clinical impact of the model usually
receiving more attention.
Here we aim to contribute to the literature by fully de-
scribing and discussing the methods implemented in a
prognostic modelling study which was previously pub-
lished according to the TRIPOD (Transparent reporting
of a multivariable predication model for Individual Prog-
nosis or Diagnosis) reporting guidelines [10]. The study
aimed to train and test a prognostic model for overall sur-
vival in TNE patients with newly diagnosed multiple mye-
loma [11]. This example is chosen, as there was missing
covariate data within the training dataset. The choice to
impute this data influenced the implemented methods
throughout the development and validation processes.
Methods
Statistical analyses were largely undertaken in R: a lan-
guage and environment for statistical computing (R Core
Team, Vienna, Austria). SAS (version 9.4; SAS Institute,
Cary, NC, USA) was used to organize the data and pro-
duce graphics where required.
Preliminary work
The training dataset for this study was the non-intensive
pathway of the National Cancer Research Institute
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(NCRI) Myeloma XI trial (ISRCTN49407852). Myeloma
XI is a phase III trial in which newly diagnosed trans-
plant ineligible patients with multiple myeloma were
randomised to receive CTDa (attenuated cyclophospha-
mide, thalidomide, and dexamethasone) or CRDa (atten-
uated cyclophosphamide, lenalidomide, and
dexamethasone) between 2010 and 2015. Full details of
the trial design and results have been reported elsewhere
[12, 13].
Clinical members of the Myeloma XI Trial Manage-
ment Group proposed potential prognostic factors for
overall survival to be considered for inclusion in the
prognostic model. Each continuous variable was mod-
elled as such, over the alternative approach of dichotom-
izing, to retain all the information they provided [3] and
were assessed for normality using histograms and trans-
formed where appropriate [14]. Each categorical variable
was assessed to see if there was a natural ordering and it
should be considered an ordinal variable. Ordinal vari-
ables were addressed using polynomial contrasts. These
investigations and decisions were made so that the ap-
propriate imputation model was selected for each covari-
ate. This ensured that the functional form of the
variables was specified at the start of the study.
It is suggested in the literature that a predictor which
is highly correlated with another predictor will contrib-
ute little independent information and can therefore be
excluded before variable selection [4]. In order to deter-
mine which variables should be included in the model
building process, each pair of potential prognostic fac-
tors were compared graphically. Two continuous vari-
ables were compared using a scatter plot, two
categorical variables were compared using a stacked bar
chart and pairs of continuous and categorical variable
were compared using a box plot. If two variables were
considered to be highly correlated with each other, then
only one of the variables was selected for the model
building stage, according to clinical utility rather than
statistical significance.
The preliminary work was conducted within R using
the ggplot2 package [15].
Model building
To assess the extent of missing covariate data within the
training dataset, the percentage of missing data within
each variable was estimated. It was pre-specified that if
no variable had a greater than 25% of missing data, ten
imputed datasets would be generated [16]. Had this been
violated, the number of imputed datasets would have
equalled the proportion of missing data based on the
commonly applied ‘rule of thumb’ [14] and the efficiency
gained when increasing the number of datasets would
have also been investigated [17].
Missing covariate data was imputed using multiple im-
putation by chained equations (MICE) as advocated in
the literature [3]. The continuous variables were im-
puted using a linear regression model and predictive
mean matching, whereas the ordinal variables were im-
puted using an ordinal regression model. Imputation
was conducted in the order of variables with the least to
the most missing data [14]. Each imputation model
regressed the variable under consideration on the
remaining five prognostic variables, the auxiliary variable
sex (male or female), survival time in months and the
survival indicator (death or censored). Despite the train-
ing data being taken from a clinical trial, randomised
treatment allocation was not included in the imputation
model. We made this decision because firstly, as treat-
ment in myeloma is constantly evolving, including treat-
ment as a proposed prognostic factor would limit the
model’s applicability, and secondly the randomisation
treatment for induction in Myeloma XI was not effective
[13]. However, this decision might not be justified in a
situation where there is a significant treatment effect. In
addition, for simplicity, survival time in months was
chosen to represent the survival outcome rather than
the Nelson-Aalen estimator of the baseline cumulative
hazard as recommended by White and Royston [18], as
the aim here was not to focus on the imputation model,
but the implication of imputation on the development
and validation of the prognostic model.
As a penalised multivariable model was planned, fol-
lowing imputation the continuous variables were stan-
dardised within each imputed dataset using the mean
and population standard deviation [19, 20]. In an im-
puted dataset of size n where xi is the i
th observation of
continuous variable x for i = 1, …, n with mean x , the








The standardisation was implemented to ensure that
the continuous variables were penalised equally within
the model building process. However, the ordinal vari-
ables were not standardised as they were modelled using
polynomial contrasts and were therefore already being
considered on a similar scale. In addition, it was thought
that standardisation of the categorical variables would
limit their interpretability in the estimated prognostic
model and therefore they were not standardised.
Univariate analysis was conducted. This regressed each
proposed prognostic factor on overall survival in a Cox
proportional hazards model in turn. The univariate
models were used to determine whether, when consid-
ered alone, the proposed prognostic factor was predict-
ive of overall survival and for informal comparison with
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the multivariable model results, but, as per the guidance
in the literature [4], not to determine which variables
should be included in the multivariable model.
For multivariable analysis incorporating variable selec-
tion [4], a penalised Cox proportional hazards model
was implemented. This statistical model is an extension
of the standard Cox model in which an additional con-
straint is applied to the estimation of the parameters.
For this analysis, the LASSO (least absolute shrinkage
and selection operator) penalty term was applied and







where ℓ(β) represents the partial log-likelihood of the
Cox model, λ the penalty term and ∣βi∣ the absolute
value of the ith parameter in the proposed model. The
additional constraint, ∑i|βi|, results in some coefficients
being shrunk to zero [19, 20].
The same penalty parameter λ∗ was applied within
each imputed dataset to reduce the variability of variable
selection across the imputed datasets [21]. The penalty
parameter was obtained as follows. First, the optimum
value of the penalty parameter within each imputed
dataset was derived using a cross-validation process as
proposed by Simon et al. [22]. The mean of the
optimum values across the imputed datasets was calcu-
lated and defined as the penalty parameter (λ∗) for the
model building process. Note that the lambda sequence
for the cross-validation process was obtained from the
first iteration of cross-validation.
A penalised Cox model that regressed overall survival
on the potential prognostic factors was estimated in each
imputed dataset with penalty parameter λ∗. In addition,
as standard errors are not readily interpretable in a
penalised model [23], bootstrap standard errors for the
coefficients were derived using 100 resamples within
each imputed dataset.
The prognostic model was obtained by combining the
coefficients and bootstrap standard errors from each im-
puted dataset by Rubin’s rules [16]. If a variable was in-
cluded in a subset of the models derived, the total
number of imputed datasets, ten, was used as the de-
nominator in Rubin’s rules to combine the results
together.
The following R packages were used during the model
building process; mice [24], survival [25], hdnom [26],
and glmnet [27]. To enable the packages to work to-
gether, code was written by KLR to derive the bootstrap
standard errors and combine the multivariable model re-
sults using Rubin’s rules.
Model assessment
We assessed model performance in each imputed data-
set by considering the assumptions of the penalised Cox
model, calibration and discrimination. The final model
assessment was obtained by combining or summarising
the results across the imputed datasets.
Model assumptions
The assumption of proportional hazards was tested in
each imputed dataset by regressing the weighted
Schoenfeld residuals on time in a linear regression
model for each covariate in turn instead of the more
commonly used scaled Schoenfeld residuals [28]. This
was to account for the possibility that the bootstrap
variance-covariance matrix would be singular. Propor-
tional hazards for a covariate were concluded if the re-
gression coefficient for time was not significantly
different from zero at the 5% significance level. If the
proportional hazards assumption had been violated,
time-dependent covariates and other more flexible sur-
vival models would have been considered [29].
The above was implemented using code written by
KLR.
Calibration
In order to assess the calibration of the prognostic
model, the predicted and observed probabilities were
calculated in each imputed dataset at 60 days and 1 year,
using an approach similar to that described by Harrell
[3].
The predicted probabilities were obtained by applying
the model derived within the imputed dataset to the
data. The quantiles of the predicted probabilities were
used to split the data into ten risk groups. The predicted
probability for a risk group was taken to be the median
of the predicted probabilities of individuals included in
the risk group. The observed probability for a risk group
was calculated using the Kaplan-Meier method [26].
The calibration of the prognostic model was assessed
by plotting the predicted vs observed probability plots
for each imputed dataset. This method was chosen as
the preferred shrinkage estimate could not be easily
combined using Rubin’s rules to obtain an overall meas-
ure of calibration performance [30]. Therefore, it was
decided to assess calibration graphically rather than with
a single estimate.
The above was implemented using the package hdnom
[26] and ggplot2 [15].
Discrimination
To assess the discrimination of the prognostic model, it
was first assessed in each imputed dataset using the
prognostic separation D-statistic (D-statistic). The D-
statistic was used as, unlike other measures, it could be
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calculated within each imputed dataset and then com-
bined via Rubin’s rules without the need for any robust
methods [30].
The D-statistic is defined as the slope coefficient of a
model for overall survival on the scaled rankits [31]. It
was calculated in each imputed dataset (of sample size n)
by applying the following steps:
I. The prognostic index (linear predictor) was
calculated for each individual
II. The values calculated in I were ordered from
smallest to largest and assigned a position (i = 1, …,
n)














IV. The scaled rankit, zi, was assigned to the individual
in position i, i.e. the smallest scaled rankit was
assigned to the individual with the smallest
prognostic index
V. Overall survival was regressed on the scaled rankits
in a Cox regression model
VI. The regression coefficient of the scaled rankits was
defined as the D-statistic
The D-statistic of the prognostic model was estimated
by combining the results in each imputed dataset using
Rubin’s rules. This quantity is referred to as the com-
bined D-statistic.
The above was implemented using the survival [25]
package in conjunction with code written by KLR to cal-




So that all of the data in the training dataset could be
used within the model building process, a bootstrap in-
ternal validation process was implemented [3]. Discrim-
ination performance in terms of the D-statistic was used
to measure acceptable performance for the internal val-
idation process. To ensure that the approach of multiple
imputation was accounted for within the validation
process [21], the internal validation process was imple-
mented using the following steps:
I. A sample with replacement was drawn from the
incomplete training data
II. The model building process detailed above,
including the imputation, was repeated to give ten
imputed datasets, ten models and ten D-statistics
III. The results of step II were combined using Rubin’s
rules to give a sample prognostic model and a
sample D-statistic
IV. The sample prognostic model was applied to the
ten imputed datasets obtained in the original model
building process and a D-statistic was obtained
V. The D-statistics obtained in step III were combined
using Rubin’s rules and the result referred to as the
internal validation D-statistic
VI. The difference between the internal validation D-
statistic and sample D-statistic was calculated and
defined as the optimism
VII. Steps I–VI were repeated 100 times
VIII. The mean optimism across the 100 iterations was
estimated
IX. The corrected D-statistic was estimated as the D-
statistic obtained in the model assessment minus
the mean optimism
The internal validation process was implemented using
code written by KLR which incorporated each element
of the model building process.
External validation
In order to determine how well the developed model
performed in data different to which it was built, an
external validation process was conducted using the
non-intensive pathway of the Medical Research Coun-
cil (MRC) Myeloma IX trial (ISRCTN68454111) as
the test dataset. Myeloma IX is a phase III trial in
which newly diagnosed transplant ineligible patients
with multiple myeloma were randomised to receive
CTDa or MP (melphalan and prednisolone) between
2003 and 2007. Full details of the trial design and re-
sults have been published elsewhere [32]. As the
model was aimed at being applied in clinic, individ-
uals in Myeloma IX were included in the test dataset
if they had all the variables included in the prognostic
model available, i.e. only individuals with complete
case data were included in the test dataset.
With the exception of imputation, the test dataset
was treated similarly to the training dataset, i.e. the
transformations applied to the continuous variables in
the training dataset were applied to those in the test
dataset. The continuous variables were also standar-
dised using values estimated in the model building
process combined using Rubin’s rules. The prognostic
index of the test model was obtained using the coeffi-
cients from the prognostic model derived in the train-
ing dataset.
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Both the calibration and discrimination of the prog-
nostic model were assessed in the test dataset using the
measures described above.
Both the assessment of calibration and discrimination
was implemented using code written by KLR. The code
for calibration was written such that the process was
equivalent to that of hdnom [26].
Risk group development
In order for the clinical community to stratify patients
easily, risk groups were derived. To account for the im-
putation process, the prognostic indexes from the
models built in the ten imputed datasets were combined
using Rubin’s rules to derive the combined prognostic
index. The tertiles of the combined prognostic index,
calculated within the training dataset, were used to tri-
chotomize individuals in both the test and training data-
sets into the risk groups: low, medium and high. The
risk groups were used to stratify Kaplan-Meier curves of
overall survival in both the test and training datasets.
The risk groups were derived in R using code written
by KLR. Kaplan-Meier curves were plotted in SAS.
Additional analysis
Following the implementation of the above methods,
additional analysis and sensitivity analysis was conducted
to investigate some of the identified limitations.
Model building and assessment
As the main analysis assessed discrimination using the
lesser known D-statistic, Uno’s C-statistic [33] was cal-
culated at both 60 days and 1 year.
In addition, to extend the assessment of calibration, a
regression model was fitted within each imputed dataset.
The regression model regressed the predicted probability
estimates on the observed probability estimates from
which an estimate of calibration slope was obtained for
both 60 days and 1 year. The ten estimates of calibration
slope were then combined using Rubin’s rules to obtain
a single estimate. Note that as only ten estimates were
used in the regression analysis, confidence intervals are
not presented for this estimate.
Model validation—calibration
The internal and external validation processes described
above were both extended to consider calibration using
the measurement of calibration slope. However, as this
work was not prospective, acceptable performance in
terms of calibration was not pre-specified.
Internal validation was conducted using an identical
process to that described for discrimination. The exter-
nal validation process applied the developed model to
the test dataset and calculated the predicted and ob-
served probabilities at 60 days and 1 year using similar
methods to that in the training dataset. From this, esti-
mates of calibration slope were obtained.
Model validation—external validation
A sensitivity analysis was conducted which imputed
missing data in the test dataset. To remain consistent
with model development, ten imputed datasets were cre-
ated using the same imputation models. The final com-
bined model from the development process was applied
within each imputed dataset and both calibration and
discrimination were assessed in the same way as in the
pre-specified analysis.
With the exception of the UnoC command, within the
SurvAUC package [34], to calculate Uno’s C-statistic, no
additional packages were used in the additional analysis
to that described in the main analysis.
Results
Preliminary work
The training dataset for this study was formed of the
1852 TNE patients in Myeloma XI. Median follow-up
was 32.7 months (inter-quartile range (IQR) 17.7–47.3
months). Six routinely collected patient characteristics
and measurements of disease were proposed by clini-
cians as potential prognostic factors: age, WHO (world
health organisation) performance status (PS), lactate de-
hydrogenase (LDH), C-reactive protein (CRP), inter-
national staging system (ISS) and the ratio of
lymphocytes to total white blood cells (L:W) (Table 1).
Of the 1852 participants in the training dataset, 1268
(68.47%) had all six potential prognostic factors recorded
and 700 (37.80%) had died at the time of analysis. Table 2
shows the missing data pattern for the six variables in
the training dataset. Of the six variables, LDH had the
largest proportion of missing data with 22.46% of partic-
ipants not having a value recorded.
Histograms of CRP and LDH (Additional File 1)
showed skewed distributions and resulted in the two
variables being transformed using the log + 1 and log
functions respectively. As a result of their natural order-
ing, WHO PS and ISS were considered as ordinal vari-
ables and modelled using polynomial contrasts. Plots of
each pair of potential prognostic factors showed that no
two variables were strongly correlated. Therefore, all six
variables were considered for inclusion in the prognostic
model (Additional File 2).
Model building
Ten imputed datasets were obtained. Univariate analysis
suggested that when considered alone all the prognostic
variables, with the exception of LDH, were significantly
associated with overall survival (Fig. 1).
The mean of the ten ‘optimal’ penalty parameters was
0.0544 (standard deviation (SD): 0.00162), indicating
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little variation across the imputed datasets. The penalty
parameter of 0.0544 resulted in some variation across
the variables selected for inclusion in the model across
the imputed datasets, where the quadratic term of WHO
PS was only included in one out of ten models. The
remaining variables were selected in all or none of the
ten models. The final prognostic model included the lin-
ear and quadratic elements of WHO PS, the linear term
of ISS, age and CRP (Fig. 1).
Model assessment
None of the linear regression models for each covariate
within each imputed dataset concluded that the
regression coefficient for time was significantly different
from zero. Therefore, no evidence was found to suggest
the proportional hazards assumption was violated.
The calibration of the prognostic model was better at
60 days post randomisation compared to one-year post
randomisation (Additional File 3). There was little vari-
ation across the D-statistics calculated in each imputed
dataset (within imputation variance 0.00393, across im-
putation variance 0.0000598). The combined D-statistic
was 0.840 (95% confidence interval (95% CI) 0.716–
0.964).
Internal validation
The mean optimism from the internal validation process
was 0.039 (SD: 0.0639). The corrected D-statistic was
0.801, resulting in the prognostic model being concluded
to perform acceptably in the training dataset (Fig. 2).
External validation
Myeloma IX recruited 849 TNE patients. Of these, 520
(61.25%) had WHO PS, ISS, age and CRP recorded and
were included in the test dataset. In the test dataset, 411
(79.04%) participants had died at the time of the ana-
lysis. Median follow-up of the test dataset was 69.2 (IQR
56.0–83.2) months. When applied, the model performed
similarly in terms of calibration, with the majority of
confidence intervals around the observed estimate cross-
ing the identity line at 60 days compared to only a few
at 1 year (Additional File 3) and discrimination where
the estimates of the D-statistics are similar and 95% con-
fidence intervals around the D-statistics in both the
training and test datasets overlap somewhat (Fig. 2).
Development of risk groups
The tertiles of the combined prognostic index were −
0.256 and 0.0283. This resulted in 617 (141 events), 618
(217 events) and 617 (342 events) participants being
categorised as low, medium and high-risk in the training
dataset and 142 (90 events), 150 (115 events) and 228
(202 events) in the test dataset. Figure 3 shows the
Kaplan-Meier estimate of the survival function for





Age Age derived at trial registration Continuous
WHO PS World Health Organisation Performance Status, a measure of the patient’s ability to do daily
tasks
Ordinal range from 0 (alive and
fully active) to 5 (dead)
LDH Lactate dehydrogenase level in the blood, a measure of tissue damage Continuous
CRP C-reactive protein level in the blood, a measure of inflammation Continuous
L:W Lymphocyte count to total white blood cell count ratio Continuous
ISS International Staging System, a measure of the severity of disease in multiple myeloma
calculated dependent on the levels of β2-microglobulm and albumin in the blood
Ordinal range from stage I to
stage III
Table 2 Missing data pattern in the training dataset. The
percentage of missing data for a single proposed prognostic
factor within the training dataset can be calculated by summing
all the patterns that include that variable
Pattern n (%)
Complete cases 1268 (68.47)
LDH 187 (10.10)
LDH and CRP 107 (5.78)
CRP 74 (4.00)
ISS 46 (2.48)
ISS and LDH and CRP 30 (1.62)
ISS and LDH 28 (1.51)
WHO PS 27 (1.46)
WHO PS and LDH 20 (1.08)
WHO PS and LDH and CRP 16 (0.86)
WHO PS and ISS and LDH and CRP 13 (0.70)
ISS and CRP 9 (0.49)
WHO PS and ISS and LDH 9 (0.49)
WHO PS and CRP 7 (0.38)
L:W and WHO PS and ISS and LDH and CRP 5 (0.27)
WHO and ISS 4 (0.22)
L:W 1 (0.05)
L:W and LDH and CRP 1 (0.05)
Age 0 (0.00)
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overall survival stratified by the risk groups in both the
training and test datasets.
Additional analysis—model assessment and validation
The median (IQR) of Uno’s C-statistic across the ten im-
putations of the training dataset was 0.665 (0.661–0.667)
at 60 days and 0.680 (0.679–0.681) at 1 year. In the test
dataset, the point estimates were 0.712 and 0.631 at 60
days and 1 year respectively.
The combined estimate of calibration slope was 2.10
at 60 days and 2.43 at 1 year in the training dataset and
5.44 at 60 days and 2.63 at 1 year in the test dataset.
The average optimism across the one hundred
bootstrap samples was − 3.65 for 60 days and − 2.47
Fig. 1 Results of the univariate and multivariable analysis conducted within the training dataset. The black squares and solid horizontal lines
represent the estimate and the associated 95% confidence interval of the proposed prognostic model within a univariate Cox model. The black
circles and dashed horizontal lines represent the estimate and the associated 95% confidence interval of the proposed prognostic model within a
multivariable penalised Cox model, following the combination of coefficients and bootstrap standard errors across ten imputed dataset using
Rubin’s rules. If there are no multivariable results for a variable, then this was penalised to zero during the model building process and not
included in the final model
Fig. 2 Results of the internal and external validation processes. The points represent the point estimates of the various discrimination measures
and the horizontal lines show the 95% confidence intervals, where appropriate
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for 1-year post-randomisation. The corrected calibra-
tion slopes were therefore 5.74 and 4.90,
respectively.
Additional analysis—multiple imputation sensitivity
analysis
The test dataset for the sensitivity analysis considering
multiple imputation included all 849 TNE patients from
Myeloma IX. At the time of analysis, 651 participants had
died. Median follow-up was 68.8 (IQR 56.1–82.0). Table 3
shows the missing data pattern for the six variables in the
test dataset. Of the six variables, LDH had the largest pro-
portion of missing data with 44.41% of participants not
having a value recorded.
The predicted versus observed probability plots at 60
days and 1 year are shown in Additional File 4. The
combined estimate of calibration slope was 5.85 at 60
days and 3.10 at 1 year. The combined D-statistic (95%
CI) was 0.666 (0.536–0.795).
Discussion
Here we have described in detail the methods imple-
mented during both the development and validation
Fig. 3 Kaplan-Meier curves for overall survival by the derived risk groups in the test and training datasets
Table 3 Missing data pattern in the test dataset. The
percentage of missing data for a single proposed prognostic
factor within the test dataset can be calculated by summing all
the patterns that include that variable
Pattern n (%)
Complete cases 361 (42.52)
LDH 157 (18.49)
LDH and CRP 140 (16.49)
CRP 91 (10.72)
ISS and LDH 42 (4.95)
ISS and LDH and CRP 33 (3.89)
ISS 10 (1.18)
ISS and CRP 7 (0.82)
LW ratio and LDH 2 (0.24)
WHO PS and LDH and CRP 2 (0.24)
LW ratio and CRP 1 (0.12)
LW ratio and ISS 1 (0.12)
WHO PS and ISS and LDH and CRP 1 (0.12)
WHO PS and CRP 1 (0.12)
Age 0 (0)
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processes of a prognostic model for a survival outcome,
the clinical impact of which has been discussed previ-
ously [11]. Figure 4 is an overview of the implemented
methods and shows how the processes in the develop-
ment and validation of a prognostic model interlink. The
decision to use these methods and choices on how they
were implemented were driven by the existing guidance
on the development and validation of prognostic models
[3–5] and also by their viability of application in con-
junction with multiple imputation.
The training dataset of this study was a subset of a
large phase III randomised controlled trial. The data was
chosen as it was believed to be representative of the
population of interest. However, as the proposed prog-
nostic factors were not stratification factors, there was
missing data present in five out of the six variables.
Missing data can be categorised as three mechanisms:
missing completely at random (MCAR), missing at ran-
dom (MAR) and missing not at random (MNAR) [35].
The mechanism assumed determines whether a
complete case analysis is appropriate. For example,
under the MCAR assumption a complete case analysis is
appropriate. In addition, for MAR and MNAR, a
complete case analysis may be appropriate if missingness
does not depend on outcome [36]. However, in either
case, it may not be optimal due to the reduction in sam-
ple size. In this study, all of the proposed variables were
patient characteristics and measurements of disease,
which are routinely measured as part of standard prac-
tice prior to a patient starting treatment. In the case of
myeloma patients, it is likely that one of these variables
is missing due to another similar test being performed
instead. Because of this, we assumed the data to be
MAR rather than MNAR. As such, missing covariate
data was imputed using MICE. MICE was chosen as it is
recommended for use in the literature and because it in-
volves multiple datasets being created, meaning that un-
certainty is considered in the process compared to single
imputation methods such as mean imputation [37]. If a
complete case analysis or single imputation method had
been deemed appropriate, the limitations around model
assessment would have been avoided, with the com-
monly used measurements of calibration and discrimin-
ation easily applicable and available to assess acceptable
model performance in both the training and test
datasets.
The combination of multiple imputation and penalised
Cox regression raises the question of how best to
Fig. 4 An overview of the implemented methods. The dashed border represents the steps repeated from the model building process in the
internal validation process
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combine results across imputed datasets when some
models include a variable and some do not. The ap-
proach taken here is the same as that taken by Musoro
et al. [21] where despite variables being penalised and
excluded in one or more models across the imputed
datasets, the number of imputed datasets in the calcula-
tions of Rubin’s rules remains the same. From our per-
spective, this is appropriate as it represents that
penalisation has occurred in some, but not all, of the im-
puted datasets.
The main challenge of this work was appropriately
assessing how the developed model performed in terms
of discrimination and calibration. Throughout the litera-
ture, there are many ways in which one can assess cali-
bration or discrimination, the most common being the
C-statistic for discrimination and the shrinkage estimate
for calibration. However, for both of these measures, the
normality assumption required under Rubin’s rules is
uncertain and robust methods are required to obtain a
single estimate across the imputed datasets. Alterna-
tively, summarising these results over the imputed data-
sets using the median and interquartile range may also
be appropriate [30]. In this analysis, we assessed discrim-
ination using the lesser-used D-statistic because it can
be combined easily using Rubin’s rules. However, on re-
flection and to aid reader interpretation, we have added
Uno’s C-statistic at both 60 days and 1 year in the train-
ing and test datasets. Initially in this work, we assessed
calibration visually, using predicted versus observed
probability plots. From this, we concluded that the
model was likely over estimating the true probabilities.
However, we decided that calibration was acceptable, as
the confidence intervals cross the desired observed prob-
ability equals predicted probability line for the majority
of risk groups, across the imputed datasets in the train-
ing dataset and in the test dataset (Additional File 3).
We have subsequently investigated the measurement of
calibration slope as an assessment of calibration. This
supported our initial findings that the model was over-
estimating the observed probabilities, as the combined
estimate of calibration slope was greater than two at
both timepoints, in both datasets. However, the assess-
ment of calibration in survival models is not simple. The
derivation of risk groups reduces the number of points
used in any regression equation thus raising questions of
model misspecification and is the reason why preci-
sion estimates were not presented for this measure.
In addition, the measurement of calibration slope only
considers the point estimates from the regression
model whereas variation in the estimates should be
considered. We believe that further work is required
to determine how best to assess calibration in the
context of survival models in the presence of missing
data.
The integration of multiple imputation and internal
validation has been considered in the literature [21, 38,
39]. Vergouwe et al. [38] did not include internal valid-
ation in their methods, but questioned in the discussion
which should come first: imputation or drawing a boot-
strap sample. Musoro et al. [21] developed this and con-
sidered whether imputing prior to taking the bootstrap
sample appropriately estimated the optimism. Wahl
et al. [39] developed this further and investigated
through simulation studies and real data examples the
implications of different orderings of imputation and a
variety of resampling methods. Both investigations rec-
ommend drawing a bootstrap sample first then perform-
ing imputation. The method applied here is closer to
that conducted by Musoro rather than Wahl as the
former included additional considerations around the in-
clusion of a penalty parameter in the multivariable
model.
In contrast to model building and internal validation,
external validation was conducted using a complete case
approach. In the literature, multiple imputation has been
applied in the test dataset and the same methods could
have been considered here [38]. However, for the ana-
lysis of primacy, it was felt that the external validation
process should be representative of what will likely occur
in clinical practice— where if one variable is missing, a
score is not calculated. However, multiple imputation
was applied in a sensitivity analysis. In this analysis, the
developed model performed similarly. However, a vali-
dated and regulated process is required before real-time
imputation occurs in clinic. In the interim, we would
recommend that further research is conducted to deter-
mine the most appropriate method of imputation for ex-
ternal validation in the context of survival models by
comparing multiple imputation, subgroup mean imput-
ation or sub-models using the one-step-sweep approach
in a simulation study [40].
In this study, the decision was made to develop the
model on the larger of the two trials causing the ex-
ternal validation process to be retrospective. As the
two trials were conducted in the same population at
different points in time, recalibration of the model
coefficients and risk group boundaries was deemed
unnecessary. However, as the trials’ recruiting centres
largely overlapped and the test data was collected
prior to the training data, this validation process was
classified as retrospective rather than temporal. In
addition, as myeloma outcomes have improved over
time, it is likely that this decision is why, as can be
seen in Additional Files 3 and 4, the calibration per-
formance of the model is worse in the test dataset
compared to the training dataset.
Before the MRP can be applied in clinic, further valid-
ation processes are required as well as an impact analysis
Royle and Cairns Diagnostic and Prognostic Research            (2021) 5:14 Page 11 of 14
[41]. As the MRP was trained and tested in UK clinical
trial data, there is a question over its generalisability.
Therefore, an external validation process will be con-
ducted within the CoMMpass study (NCT01454297).
The CoMMpass study contains real-world patients from
Canada, Italy, Spain and the USA and was collected by
the MMRF (Multiple Myeloma Research Foundation) in-
dependently from the UK myeloma research community.
Therefore, it represents a dataset which is entirely exter-
nal from the data considered here. However, the
CoMMpass study represents another retrospective valid-
ation process and before the model can be used in prac-
tice, a prospective validation process should be
considered. Myeloma XIV is a UK clinical trial in TNE
patients with newly diagnosed multiple myeloma which
opened to recruitment on the 4th August 2020
(NCT03720041). The data collected will be used in a
prospective validation process, where an appropriate
sample size calculation will be considered. Taiyari [42]
has proposed a calculation that determines the required
number of events for a prospective validation study. The
calculation uses the number of events and variance of
the D-statistic observed in the training dataset and cal-
culates the required number of events in the test dataset
based on the desired width and level of the confidence
interval. Unsurprisingly, for the same width and level ob-
served in the training dataset to be observed in the test
dataset, the same number of events is required.
In this work, acceptable discrimination performance
within both the internal and external validation processes
was pre-specified. However, as it was informal and no guid-
ance exists on how to pre-specify acceptable performance
[5], it was considered problematic and removed at the re-
quest of the journal editors. A further limitation in terms of
pre-specifying performance is that both discrimination and
calibration must be considered. Therefore, future work is
required to develop methods which can compare prognos-
tic models in terms of both calibration and discrimination.
We believe that the D-statistic is an appropriate measure
for discrimination in survival models. However, calibration
remains problematic. Whilst calibration slope has been in-
vestigated since this work was initially conducted, the limi-
tations around model-misspecification and variability
discussed above suggest that calibration slope may not be
an appropriate measure to base calibration performance on.
Since this work was conducted two reviews of prog-
nostic model development and validation have been
published. The first considers the use of randomised
controlled trial data for the development and validation
of prognostic models [43]. A retrospective assessment
suggests that the data was used appropriately in terms of
consent, centre inclusion, eligibility and enrolment, pre-
dictor measurement, outcome and sample size. The only
potential criticism was the extraneous trial effects as
patients were treated, in some cases, above the standard
of care. However, this will be addressed as part of the fu-
ture validation processes outlined above. The second re-
view proposes methodological standards for the
application of prognostic models in clinical practice [44].
A retrospective assessment suggests that the methods
applied here reflect their recommendations on the iden-
tification, development, missing data and validation of
prognostic models. However, as discussed above, add-
itional work regarding validation and impact analysis is
required before the prognostic model can be applied in
practice.
Conclusion
Following guidance and examples in the literature, it was
found to be possible to build a model which accounted
for missing data in its development, assessment and val-
idation processes. This has resulted in a prognostic
model for overall survival obtained using a novel com-
bination of methods that are appropriate when covariate
data is missing. As discussed, this was not the only way
to achieve our aim and the limitations and areas for fur-
ther research have been identified.
However, this explanation of the methods provides an
additional transparent example of training and testing a
prognostic model for a time-to-event outcome when
missing covariate data is present within the training
dataset, adding to the existing literature for similar out-
comes [7, 45] and a binary outcome [38].
We hope that this example motivates other researchers
to have a similar open approach to reporting statistical
analysis and provides additional support to those who are
training and testing prognostic models in the presence of
missing covariate data within the training dataset.
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